- Home
- SOPH vs BWAY Comparison
SOPH vs BWAY Comparison
Compare SOPH & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- BWAY
- Stock Information
- Founded
- SOPH 2011
- BWAY 2003
- Country
- SOPH Switzerland
- BWAY Israel
- Employees
- SOPH N/A
- BWAY N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- BWAY Medical/Dental Instruments
- Sector
- SOPH Health Care
- BWAY Health Care
- Exchange
- SOPH Nasdaq
- BWAY Nasdaq
- Market Cap
- SOPH 206.6M
- BWAY 207.4M
- IPO Year
- SOPH 2021
- BWAY 2019
- Fundamental
- Price
- SOPH $2.93
- BWAY $8.76
- Analyst Decision
- SOPH Strong Buy
- BWAY Strong Buy
- Analyst Count
- SOPH 2
- BWAY 3
- Target Price
- SOPH $6.50
- BWAY $13.17
- AVG Volume (30 Days)
- SOPH 26.9K
- BWAY 24.4K
- Earning Date
- SOPH 05-06-2025
- BWAY 05-13-2025
- Dividend Yield
- SOPH N/A
- BWAY N/A
- EPS Growth
- SOPH N/A
- BWAY N/A
- EPS
- SOPH N/A
- BWAY 0.06
- Revenue
- SOPH $67,173,000.00
- BWAY $41,016,000.00
- Revenue This Year
- SOPH $14.86
- BWAY $351.53
- Revenue Next Year
- SOPH $22.76
- BWAY $21.84
- P/E Ratio
- SOPH N/A
- BWAY $57.37
- Revenue Growth
- SOPH 4.66
- BWAY 29.04
- 52 Week Low
- SOPH $2.58
- BWAY $5.13
- 52 Week High
- SOPH $6.28
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- SOPH 44.97
- BWAY 47.80
- Support Level
- SOPH $2.90
- BWAY $8.61
- Resistance Level
- SOPH $3.33
- BWAY $9.09
- Average True Range (ATR)
- SOPH 0.21
- BWAY 0.38
- MACD
- SOPH 0.00
- BWAY 0.05
- Stochastic Oscillator
- SOPH 21.78
- BWAY 58.73
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.